Department of Radiation Medicine, Oregon Health & Science University, Portland, OR
Carl Post, Theodore P. Braun, Ruth Etzioni, Nima Nabavizadeh
A multitude of blood-based multicancer early detection (MCED) tests assessing cancer-related alterations in circulating genomic analytes and other associated signatures are currently being developed with the potential to disrupt current single-organ screening paradigms. Pathways for clinical implementation of these novel MCED tests have not been delineated, particularly for the patients with signal positive results requiring additional confirmatory testing. In this overview, we highlight early results from prospective clinical studies testing the efficacy of genomic MCED tests in cohorts of patients without known cancer diagnoses. Additionally, we discuss a proposed professional expansion of the oncology practice relating to the diagnostic workup of individuals found to have an MCED signal positive for cancer. As MCED blood tests have the potential to dramatically upend current cancer screening paradigms and downstream cancer therapy, it is imperative for oncologists to be aware of important clinical studies and the multitude of unanswered questions. The current gaps in the clinical implication of these tests may serve as a meaningful and rewarding expansion of oncology practice.
JCO Precision Oncology
First Author: Ann Ayzman
Publish Date: Sep 19, 2024
JCO Global Oncology
First Author: Yara Rafaela Maia
Publish Date: Aug 3, 2023
Journal of Clinical Oncology
First Author: Anthony S. Robbins
Publish Date: Dec 19, 2011
Journal of Clinical Oncology
First Author: Electra D. Paskett
Publish Date: Dec 19, 2011